Mirna Therapeutics Inc (MIRN) is Downgraded by Cantor Fitzgerald to Hold

Mirna Therapeutics Inc (MIRN) was Downgraded by Cantor Fitzgerald to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Cantor Fitzgerald advised their investors in a research report released on Sep 21, 2016.

Many Wall Street Analysts have commented on Mirna Therapeutics Inc. H.C. Wainwright Initiated Mirna Therapeutics Inc on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $6.Mirna Therapeutics Inc was Downgraded by Citigroup to ” Neutral” on Aug 17, 2016. Mirna Therapeutics Inc was Downgraded by Leerink Partners to ” Mkt Perform” on Aug 16, 2016.

Mirna Therapeutics Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy microRNA Replacement Therapy focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. Its pipeline of products includes MRX34 miR-101 miR-215 let-7 and miR-16. The Company’s lead product candidate MRX34 a mimic of naturally occurring microRNA-34 (miR-34) is in Phase I clinical trial in patients with primary liver cancer advanced solid tumors and hematological malignancies. Its miR-34 is considered a key regulator of multiple oncogenes across key oncogenic pathways. The Company focuses on developing MRX34 as a monotherapy and in combination with other therapeutic modalities such as targeted therapies and immuno-oncology agents.

Mirna Therapeutics Inc

Leave a Reply

Mirna Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirna Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.